Contact Us

Yes. SIRT3 rescue experiments are well-established for mitochondrial deacetylase research: • Construct design: use a codon-modified SIRT3 sequence with a small C-terminal tag (FLAG, HA). SIRT3 has an N-terminal mitochondrial targeting sequence that is cleaved upon import — N-terminal tags must not disrupt this processing. • Catalytically-dead rescue: the H248Y mutation abolishes deacetylase activity and is the standard specificity control. • Mitochondrial localization validation: confirm mitochondrial matrix localization by appropriate compartment markers. • Functional readout: rescue should restore deacetylation of SIRT3 substrates and improve mitochondrial bioenergetics. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC19A1 (RFC)'s role in antifolate chemotherapy uptake or its function in innate immune cGAMP transport in colorectal cancer contexts. The Knockout line is the standard tool for both — methotrexate resistance in colorectal cancer is frequently associated with SLC19A1 downregulation, and the knockout serves as a defined resistance background. Overexpression is useful for restoring antifolate drug sensitivity or for studying cGAMP-STING signaling in cancer immunity contexts. For cancer therapy research, the EDITGENE SLC19A1 Knockout in HCT 116 is particularly relevant — it models methotrexate/pemetrexed-resistant colorectal cancer and enables study of STING-mediated tumor immunity in a CRC context. This product complements the parallel SLC19A1 Knockout in HEK293; HCT 116 is preferred for chemotherapy resistance studies and CRC-STING immunity research. Rescue with wild-type or transport-deficient SLC19A1 enables structure-function dissection.

Yes. SLC19A1 rescue experiments in HCT 116 are well-suited for cancer-relevant studies: • Construct design: use a codon-modified SLC19A1 sequence with a small C-terminal tag (FLAG, HA). Surface localization must be confirmed before functional studies. • Drug sensitivity rescue: methotrexate/pemetrexed sensitivity restoration in SLC19A1-null HCT 116 confirms transport rescue and serves as a functional positive control. • STING signaling rescue: cGAMP-induced IFN-β reporter activation restoration in cancer cell context. • Functional readout: rescue should restore both folate transport (methotrexate sensitivity) and cGAMP transport (STING activation) — confirming the dual transport function. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC25A22 (glutamate carrier 1, GC1)'s role as a mitochondrial glutamate-H⁺ symporter or modeling early infantile epileptic encephalopathy type 3 (EIEE3). The Knockout line is the standard tool for asking whether GC1 is required for mitochondrial glutamate import — GC1 imports glutamate into mitochondria for catabolism, ammonia detoxification (urea cycle precursor supply), and oxidative phosphorylation substrate provision. Overexpression is useful for studying disease-associated mutations or for biochemical reconstitution. For mitochondrial glutamate metabolism research, the EDITGENE SLC25A22 Knockout in HCT 116 enables study of glutamate-dependent mitochondrial functions. SLC25A22 mutations cause EIEE3 (autosomal recessive, severe neonatal epilepsy with brain malformations) — disease variant rescue enables genotype-function correlation studies. Rescue with wild-type or transport-deficient GC1 is the standard specificity control.

Yes. GC1 rescue experiments are well-established for mitochondrial glutamate biology: • Construct design: use a codon-modified SLC25A22 sequence with a small C-terminal tag (FLAG, HA). GC1 has the SLC25 canonical architecture. • Mitochondrial localization validation: confirm mitochondrial inner membrane localization. • EIEE3 disease mutation rescue: patient-derived SLC25A22 mutations (e.g., P206L, G236W, R155Q) enable disease genotype-function correlation. • Functional readout: rescue should restore mitochondrial glutamate import (in vitro swelling assays) and glutamate-supported respiration (Seahorse). HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC1A5 (ASCT2)'s role as the principal glutamine transporter or its emerging functions in cancer metabolism and mTORC1 signaling. The Knockout line is the standard tool for asking whether ASCT2 is required for glutamine uptake — ASCT2 is upregulated in many cancers and is the major route for glutamine entry in glutamine-addicted tumor cells, including colorectal cancer. Overexpression is useful for studying ASCT2 in cancer metabolism contexts or for assessing inhibitor specificity. For cancer metabolism research, the EDITGENE ASCT2 Knockout in HCT 116 is highly relevant — colorectal cancer cells frequently exhibit glutamine dependence, and ASCT2 is a validated cancer metabolism target. Rescue with wild-type or transport-deficient ASCT2 is the standard specificity control. The knockout serves as a critical genetic specificity tool for ASCT2 inhibitors (V-9302, IMD-0354 derivatives) and ASCT2-targeting therapeutic antibodies in development.

Yes. ASCT2 rescue experiments are well-established for cancer metabolism research: • Construct design: use a codon-modified SLC1A5 sequence with a small C-terminal tag (FLAG, HA). ASCT2 has 8 transmembrane domains in the canonical SLC1 architecture — preserve plasma membrane targeting determinants. • Transport-deficient rescue: substrate-binding pocket mutations enable distinguishing transport activity from non-transport functions. • V-9302-resistant rescue: ASCT2 inhibitor-resistant variants enable on-target validation of ASCT2-targeting compounds. • Functional readout: rescue should restore glutamine uptake activity and downstream mTORC1 signaling and proliferation phenotypes. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying RXRA's role as the dominant retinoid X receptor in most tissues or its specific contributions distinct from RXRB and RXRG. The Knockout line is appropriate for asking whether RXRA is required for nuclear receptor signaling — RXRA is the most broadly expressed RXR paralog and the principal heterodimerization partner for RAR, PPAR, LXR, FXR, VDR, TR, and other partner receptors in most cellular contexts. Overexpression is useful for studying RXRA gain-of-function or for testing rexinoid pharmacology. Important consideration: RXRA, RXRB, and RXRG have substantial functional overlap as heterodimer partners. Single RXRA knockout in A-549 may show partial phenotypes if RXRB compensates — RXRG is typically less expressed in non-hematopoietic and non-neural tissues. For lung cancer nuclear receptor research, the EDITGENE RXRA Knockout in A-549 is informative for studies focused on RXRA-specific contributions to lung cancer biology and retinoid signaling. This product complements the parallel RXRB Knockout in HAP1 and the RXRA & RXRB Double Knockout in A-549; the single RXRA knockout in A-549 enables direct paralog-specific functional comparisons within the same lung cancer background. Rescue with wild-type or DNA-binding/ligand-binding-deficient RXRA enables structure-function studies.

Yes. RXRA rescue experiments require attention to multi-domain nuclear receptor architecture and paralog considerations: • Construct design: use a codon-modified RXRA sequence with a small C-terminal tag (FLAG, HA). RXRA has the canonical nuclear receptor architecture (N-terminal A/B with AF-1, DNA-binding C domain, hinge D, ligand-binding E domain with AF-2) — preserve all elements. • DNA-binding-deficient rescue: zinc finger DBD mutations (e.g., conserved C-to-S substitutions) abolish DR-element binding and serve as the standard specificity control for transcription-dependent functions. • Ligand-binding-deficient rescue: LBD mutations affecting 9-cis-retinoic acid or rexinoid binding enable distinguishing ligand-dependent from constitutive activities — useful for separating bexarotene-induced effects from baseline RXRA function. • Paralog considerations: RXRB expression status in rescue cells aids interpretation given functional redundancy. For comprehensive paralog dissection, single-RXRA rescue in the RXRA & RXRB Double Knockout (also available in A-549) provides cleaner readouts than rescue in this single-RXRA knockout. • Functional readout: rescue should restore RAR-RXR retinoid signaling (DR5 reporter), PPAR-RXR lipid metabolism signaling (DR1 reporter), and target gene expression in lung cancer-relevant contexts. A-549 transduces efficiently with lentivirus and supports stable rescue line generation in the same lung cancer background as the RXRB and double-knockout products, enabling rigorous comparative analysis across the three-line series.

The choice depends on whether you are studying SDC1 (Syndecan-1, CD138)'s role as a heparan sulfate proteoglycan involved in growth factor signaling, cell adhesion, and matrix interactions, or its emerging functions in cancer biology and viral entry. The Knockout line is the standard tool for asking whether SDC1 is required for these processes — particularly relevant in A-549, where SDC1 has been implicated in lung cancer biology and serves as the principal SARS-CoV-2 attachment factor through its heparan sulfate chains. Overexpression is useful for studying SDC1's role in growth factor sequestration (FGF2 reservoirs) or as a co-receptor. For SDC1 research, the EDITGENE Knockout in A-549 is highly informative — A-549 is an established lung cancer model and a workhorse for respiratory virus research, including SARS-CoV-2 entry mechanisms. Rescue with wild-type or HS-chain-deficient (HS-attachment site mutant) SDC1 enables structure-function studies separating heparan sulfate chain functions from the core protein. SDC1 is a clinical multiple myeloma marker (CD138) and an emerging cancer therapeutic target (indatuximab ravtansine ADC).

Yes. SDC1 rescue experiments require attention to heparan sulfate biology: • Construct design: use a codon-modified SDC1 sequence with a small intracellular C-terminal tag (FLAG, HA). SDC1 is a type I membrane protein with an N-terminal extracellular domain containing HS attachment sites and a short cytoplasmic C-terminal tail. • HS-deficient rescue: HS-attachment site mutations (typically S37A/S45A/S47A) abolish heparan sulfate chain attachment and serve as the standard control for distinguishing HS-mediated functions from core protein functions. • Shedding-resistant rescue: ADAM17/MMP-resistant mutations enable studies of full-length versus shed SDC1 functions. • Functional readout: rescue should restore HS-dependent FGF2 binding/signaling, SARS-CoV-2 spike attachment, and other heparan sulfate-mediated activities. A-549 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC20A2 (PiT-2)'s role as a sodium-dependent phosphate transporter or modeling primary familial brain calcification (PFBC, Fahr disease). The Knockout line is the standard tool for asking whether PiT-2 is required for cellular phosphate uptake — PiT-2 is widely expressed and is the principal type III sodium-phosphate cotransporter in many tissues including brain endothelium and astrocytes. Overexpression is useful for studying PFBC-associated mutations or for testing transport activity in heterologous systems. For phosphate transporter research, the EDITGENE SLC20A2 Knockout in HCT 116 enables study of cellular phosphate handling and downstream PiT-2-dependent processes. SLC20A2 mutations are the most common cause of autosomal dominant PFBC, characterized by basal ganglia and cerebral calcifications — disease variant rescue enables genotype-function correlation studies. SLC20A1 (PiT-1) paralog expression analysis aids interpretation given functional overlap.

Yes. PiT-2 rescue experiments require attention to topology and disease variant biology: • Construct design: use a codon-modified SLC20A2 sequence with a small C-terminal tag (FLAG, HA). PiT-2 has 12 transmembrane domains — N-terminal tags must not disrupt topology. • Surface localization validation: confirm plasma membrane localization before transport assays; many PFBC mutations cause ER retention rather than transport defects. • PFBC mutation rescue: patient-derived dominant-acting SLC20A2 mutations enable disease genotype-function studies. • Functional readout: rescue should restore sodium-dependent phosphate uptake measured by ³²P-orthophosphate uptake. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC16A7 (MCT2)'s role as a high-affinity monocarboxylate transporter or its specific contributions distinct from MCT1 (SLC16A1) and MCT4 (SLC16A3). The Knockout line is the standard tool for asking whether MCT2 is required for lactate, pyruvate, and ketone body transport in contexts where MCT2 dominates over other MCT family members. Overexpression is useful for studying MCT2 in heterologous systems or for testing inhibitor selectivity. For monocarboxylate transport research, the EDITGENE MCT2 Knockout in HCT 116 enables study of high-affinity lactate handling in a colorectal cancer context. MCT2 has higher affinity for lactate than MCT1/MCT4 (Km ~0.7 mM vs ~5 mM and ~30 mM respectively) — making it particularly relevant in tissues where physiological lactate concentrations are low. Rescue with wild-type or transport-deficient MCT2 enables structure-function studies. Note that MCT2 requires embigin (EMB), not basigin (CD147), as its ancillary protein.

Yes. MCT2 rescue experiments require attention to embigin partnership: • Construct design: use a codon-modified SLC16A7 sequence with a small C-terminal tag (FLAG, HA). MCT2 has 12 transmembrane domains. • Embigin partnership: MCT2 requires embigin (EMB), not basigin (CD147), for surface trafficking — confirm embigin expression in rescue cells or co-express embigin for full activity. • Transport-deficient rescue: substrate-binding pocket mutations enable structure-function studies. • Functional readout: rescue should restore high-affinity monocarboxylate uptake at low substrate concentrations (where MCT2 dominates over MCT1). HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.